As part of our market update series, please see the summary below of what we saw in the convertible market in Q1 2022. New Issuance. Q1 2022 saw 11 new issue convertible deals (all debt) with a total volume of $6.1bn, which marks the lowest level of issuance since Q4 2018 ($5.3bn across 16 ... >>>Read More
What You Need to Know as You Navigate the Market and an Ever-Evolving Life Sciences Financing Landscape
The financing landscape for life sciences issuers has transformed over the last 5 years. In this three-part series, we will cover 1) the evolution of the typical life sciences IPO, 2) post-IPO financing dynamics and the importance of laying the foundation for successful capital raises, and 3) later ... >>>Read More
Q4 2021 Convertible Market Review
As part of our market update series, please see the summary below of what we saw in the convertible market in Q4 2021. New Issuance. Q4 2021 saw 27 new issue convertible deals (all debt) with a total volume of $18.1bn, which brought total 2021 issuance to $92.8bn across 155 deals. 2021 was the ... >>>Read More
Post-SPAC Warrant Redemption Features (Part 3)
This is the third of a series of posts examining the redemption features of warrants in post-SPAC public companies. In the first post, we described typical redemption features in warrants. The second post discussed how issuers might economically analyze whether and when to redeem the warrants. ... >>>Read More
Q3 2021 Convertible Market Review
As part of our market update series, please see the summary below of what we saw in the convertible market in Q3 2021. New Issuance. Q3 2021 saw 23 new issue convertible deals (22 debt & 1 mandatory) with dollar volumes of $15.0bn, compared to $17.0bn across 30 deals from Q2 2021 and $19.9bn ... >>>Read More
- « Previous Page
- 1
- …
- 5
- 6
- 7
- 8
- 9
- …
- 19
- Next Page »